Page 85 - Sohini Das

More Covid vaccine supplies lined up as India gets ready for Phase 3 drive

Bharat Bio may add 200 mn doses if needed; Serum to have 2.5 mn capacity by year-end

Covid-19 vaccination: Ready for round-3, but no decision on who'll pay

Public vaccination back-end technology in place, private sector role likely in procuring doses for staff

Govt likely to allow Covid-19 vaccine in private market by March end

Low turnout for vaccination so far a likely reason

Russia's Sputnik V 91.6% effective with good safety profile in trials

In the interim efficacy analysis, data from 19,866 volunteers were included

Bharat Biotech inks pact to commercialise Covid-19 vaccine Covaxin in US

Ocugen, a Nasdaq-listed firm, focuses on developing and commercialising gene therapies to cure blindness diseases

'Get well soon' outlay: Health care gets best-ever shot in Budget 2021

Allocation jumps 118% over RE to Rs 2.23 trillion; Rs 35,000 cr earmarked for Covid vaccination

Budget 2021 to spend Rs 2.23 trn on healthcare, raising outlay by 137%

New central scheme called Atmanirbhar Swasth Bharat Yojana gets Rs 64,180 crore in Sitharaman's budget

Lupin plans expansion, aims to enter Chinese market in the next one year

The company has now decided to focus on specialty drugs. The annual price cuts made the Japanese generics market unattractive

Cipla's net profit zooms 113% in December quarter; revenue up 18%

The total revenue from operations came in at Rs 5,169 crore and the net profit stood at Rs 748 crore, up 113 per cent.

Sun Pharma Q3 PAT doubles to Rs 1,852 cr, rides on record quarterly revenue

The company has repaid debt of about $490 million in 9MFY21; filings for 90 ANDAs await US FDA approval

Dr Reddy's reports Q3 profit of Rs 20 crore, revenues at Rs 4,930 crore

DRL said the Q3 results were impacted primarily due the non-recognition of deferred tax assets on impairment.

Dr Reddy's Laboratories likely to launch Sputnik V under EUA in March

The bridge trials on 1,600 participants in India was ongoing. The phase 2 trials are completed and the phase 3 is on.

Novavax Covid-19 vaccine shows 89% efficacy in UK clinical trials

The trial has assessed its efficacy during a period with high transmission and with a new UK strain of the virus

Preliminary data from animal study shows immune response for ZyCoV-D

ZyCoV-D can remain stable at 25 degrees Celsius for months

Bharat Biotech's Covaxin effective against Covid-19 UK strain: ICMR

The genome of the UK-variant has 17 mutations, eight of those were in the spike protein domain

Serum Institute looking at bilateral deals to supply Covishield vaccine

To raise manufacturing capacity by 30% over next 2 months from present 2.4 mn doses

Dr Reddy's, Zuventus get nod to conduct Covid-19 trials on repurposed drugs

NeuroRx and Relief Therapeutics have partnered to develop a drug called RLF-100 that has anti-inflammatory and anti-cytokine activity properties.

Wockhardt, IIL discuss manufacturing tie-up with US vaccine major Moderna

Around November, IIL had indicated that it was open to discussions with the US major.

Indemnity clause: Serum Institute of India knocks on govt door again

SII Chief Executive Officer Adar Poonawalla earlier indicated legal indemnity was required to ensure that the vaccination drive could be completed smoothly

Nasal vaccine: Bharat Bio told to submit efficacy data from Phase-3 trials

India may start vaccine exports as soon as today